User fee date of Takeda's febuxostat passes without action
This article was originally published in Scrip
Executive Summary
The US FDAhas said that it was not be able to complete its review of the NDA for Takeda's anti-gout medication, Uloric (febuxostat, licensed from Teijin), before its user fee date of January 18th.